BriaCell Therapeutics Corp. BCT.TO

BCT.TO Company Overview

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on the development of novel immunotherapy-based treatments for cancer, with a primary emphasis on advanced breast cancer. The company operates within the biopharmaceutical and oncology therapeutics industries, targeting patients with limited treatment options, particularly those with metastatic disease. BriaCell’s core approach centers on activating a patient’s immune system to recognize and destroy cancer cells using proprietary cell-based and off-the-shelf immunotherapies.

The company’s principal revenue drivers are currently research and development activities, as BriaCell does not generate commercial product revenue and remains dependent on equity financing and strategic collaborations. Its lead programs are designed to address unmet medical needs in oncology, positioning BriaCell as a niche innovator in personalized and allogeneic cancer immunotherapy. Founded in the early 2000s, BriaCell has evolved from early immuno-oncology research into a company advancing multiple clinical-stage assets, supported by regulatory engagement in both Canada and the United States.